SML Biopharm have mRNA platform with optimized UTR and poly(A) tail for enhanced stability and expression.
We are advancing drug pipelines and a next-generation mRNA platform, while independently developing
lipid nanoparticles (LNPs) for efficient delivery, driving effective R&D and rapid progress in the field.
